

Form 62-103F1

Required Disclosure under the Early Warning Requirements

State if this report is filed to amend information disclosed in an earlier report. Indicate the date of the report that is being amended.

Item 1 – Security and Reporting Issuer

1.1 State the designation of securities to which this report relates and the name and address of the head office of the issuer of the securities.

This report relates to common shares (“**Common Shares**”) in the capital of ChroMedX Corp. (“**ChroMedX**”)

ChroMedX’s head office address is:

401 Bay Street, 16th Floor
Toronto, Ontario
M5H 2Y4

1.2 State the name of the market in which the transaction or other occurrence that triggered the requirement to file this report took place.

Securities were disposed of on the Canadian Securities Exchange (the “**CSE**”) or carried out privately.

Item 2 – Identity of the Acquiror

2.1 State the name and address of the acquiror.

Invidx Corp. (the “**Invidx**”)
6 Trout Lily Avenue
Markham, ON L3S 4C1

2.2 State the date of the transaction or other occurrence that triggered the requirement to file this report and briefly describe the transaction or other occurrence.

On December 15, 2014, Invidx filed an early warning report (the “**Previous EWR**”) disclosing ownership of a total of 20,474,552 Common Shares, representing 47.75% of the total Common Shares (based on 42,874,644 Common Shares issued and outstanding at such date).

The number of Common Shares owned by Invidx did not change from the Previous EWR until December 27, 2017. Between December 27, 2017 and June 20, 2018, Invidx disposed of a total of 1,107,500 Common Shares in a series of dispositions through the facilities of the CSE or carried out privately (the

“**Dispositions**”). This represents a decrease in Invidx’s position in ChroMedX of approximately 5.41%.

As at June 20, 2018 following the Dispositions, Invidx owned 19,367,052 Common Shares, representing 19.14% of the total Common Shares (based on 101,177,362 Common Shares issued and outstanding at such date).

2.3 State the names of any joint actors.

Not applicable.

Item 3 – Interest in Securities of the Reporting Issuer

3.1 State the designation and number or principal amount of securities acquired or disposed of that triggered the requirement to file this report and the change in the acquiror’s securityholding percentage in the class of securities.

Between December 27, 2017 and June 20, 2018, Invidx disposed of 1,107,500 Common Shares. The result of the Dispositions was a decrease in Invidx’s position in ChroMedX by approximately 5.41%.

As at June 20, 2018 following the Dispositions, Invidx owned 19,367,052 Common Shares, representing 19.14% of the total Common Shares (based on 101,177,362 Common Shares issued and outstanding at such date).

3.2 State whether the acquiror acquired or disposed ownership of, or acquired or ceased to have control over, the securities that triggered the requirement to file this report.

Invidx completed the Dispositions, resulting in the disposition of a total of 1,107,500 Common Shares which triggered the requirement to file this report.

3.3 If the transaction involved a securities lending arrangement, state that fact.

Not applicable.

3.4 State the designation and number or principal amount of securities and the acquiror’s securityholding percentage in the class of securities, immediately before and after the transaction or other occurrence that triggered the requirement to file this report.

Prior to the Dispositions, Invidx owned a total of 20,474,552 Common Shares.

Following the Dispositions, Invidx directly owns an aggregate of 19,367,052 Common Shares, representing 19.14% of the total Common Shares (based on 101,177,362 Common Shares issued and outstanding at such date).

3.5 State the designation and number or principal amount of securities and the acquiror's securityholding percentage in the class of securities referred to in Item 3.4 over which

- (a) the acquiror, either alone or together with any joint actors, has ownership and control,**

Invidx directly owns an aggregate of 19,367,052 Common Shares, representing 19.14% of the total Common Shares (based on 101,177,362 Common Shares issued and outstanding at such date).

- (b) the acquiror, either alone or together with any joint actors, has ownership but control is held by persons or companies other than the acquiror or any joint actor, and**

Not applicable.

- (c) the acquiror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Not applicable.

3.6 If the acquiror or any of its joint actors has an interest in, or right or obligation associated with, a related financial instrument involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the related financial instrument and its impact on the acquiror's securityholdings.

Not applicable.

3.7 If the acquiror or any of its joint actors is a party to a securities lending arrangement involving a security of the class of securities in respect of which disclosure is required under this item, describe the material terms of the arrangement including the duration of the arrangement, the number or principal amount of securities involved and any right to recall the securities or identical securities that have been transferred or lent under the arrangement.

State if the securities lending arrangement is subject to the exception provided in section 5.7 of NI 62-104.

Not applicable.

3.8 If the acquiror or any of its joint actors is a party to an agreement, arrangement or understanding that has the effect of altering, directly or indirectly, the acquiror's economic exposure to the security of the class of securities to which this report relates, describe the material terms of the agreement, arrangement or understanding.

Not applicable.

Item 4 – Consideration Paid

4.1 State the value, in Canadian dollars, of any consideration paid or received per security and in total.

The 1,107,500 Common Shares were disposed of for aggregate proceeds of \$209,161, as set out below.

Date	Disposition Amount	Closing Balance	Proceeds
December 27, 2017	3,000	20,471,552	1,890
January 5, 2018	26,000	20,445,552	17,300
January 9, 2018	6,500	20,439,052	4,570
January 31, 2018	2,000	20,437,052	1,330
February 9, 2018	10,000	20,427,052	5,100
February 9, 2018 ⁽¹⁾	450,000	19,977,052	0
March 8, 2018	63,000	19,914,052	26,855
March 13, 2018	10,000	19,904,052	4,055
May 11, 2018	245,000	19,659,052	69,468
May 15, 2018	151,500	19,507,552	42,313
May 24, 2018	83,500	19,424,052	21,755
May 29, 2018	20,000	19,404,052	5,215
June 20, 2018	37,000	19,367,052	9,310
Totals	1,107,500		\$209,161

NOTE:

(1) Common Shares were donated to charity or gifted for no consideration.

4.2 In the case of a transaction or other occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, disclose the nature and value, in Canadian dollars, of the consideration paid or received by the acquiror.

Not applicable.

4.3 If the securities were acquired or disposed of other than by purchase or sale, describe the method of acquisition or disposition.

Not applicable.

Item 5 – Purpose of the Transaction

State the purpose or purposes of the acquiror and any joint actors for the acquisition or disposition of securities of the reporting issuer. Describe any plans or future intentions which the acquiror and any joint actors may have which relate to or would result in any of the following:

- (a) the acquisition of additional securities of the reporting issuer, or the disposition of securities of the reporting issuer;**
- (b) a corporate transaction, such as a merger, reorganization or liquidation, involving the reporting issuer or any of its subsidiaries;**
- (c) a sale or transfer of a material amount of the assets of the reporting issuer or any of its subsidiaries;**
- (d) a change in the board of directors or management of the reporting issuer, including any plans or intentions to change the number or term of directors or to fill any existing vacancy on the board;**
- (e) a material change in the present capitalization or dividend policy of the reporting issuer;**
- (f) a material change in the reporting issuer's business or corporate structure;**
- (g) a change in the reporting issuer's charter, bylaws or similar instruments or another action which might impede the acquisition of control of the reporting issuer by any person or company;**
- (h) a class of securities of the reporting issuer being delisted from, or ceasing to be authorized to be quoted on, a marketplace;**
- (i) the issuer ceasing to be a reporting issuer in any jurisdiction of Canada;**
- (j) a solicitation of proxies from securityholders;**
- (k) an action similar to any of those enumerated above.**

Invidx disposed of Common Shares in the ordinary course.

Item 6 – Agreements, Arrangements, Commitments or Understandings With Respect to Securities of the Reporting Issuer

Describe the material terms of any agreements, arrangements, commitments or understandings between the acquiror and a joint actor and among those persons and any person with respect to securities of the class of securities to which this

report relates, including but not limited to the transfer or the voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Include such information for any of the securities that are pledged or otherwise subject to a contingency, the occurrence of which would give another person voting power or investment power over such securities, except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

Not applicable.

Item 7 – Change in Material Fact

If applicable, describe any change in a material fact set out in a previous report filed by the acquiror under the early warning requirements or Part 4 in respect of the reporting issuer's securities.

Not applicable.

Item 8 – Exemption

If the acquiror relies on an exemption from requirements in securities legislation applicable to formal bids for the transaction, state the exemption being relied on and describe the facts supporting that reliance.

Not applicable.

Item 9 – Certification

The acquiror must certify that the information in this report is true and complete in every respect. In the case of an agent, the certification is based on the agent's best knowledge, information and belief but the acquiror is still responsible for ensuring that the information filed by the agent is true and complete.

This report must be signed by each person on whose behalf the report is filed or his or her authorized representative.

It is an offence to submit information that, in a material respect and at the time and in the light of the circumstances in which it is submitted, is misleading or untrue.

Certificate

The certificate must state the following:

I, as the acquiror, certify, or I, as the agent filing this report on behalf of an acquiror, certify to the best of my knowledge, information and belief, that the statements made in this report are true and complete in every respect.

June 25, 2018

.....
Date

“Lorna Samsoundar”

.....
Signature

President

.....
Name/Title